The European Association for the Study of Obesity (EASO) is a leading voice of obesity science, medicine and community in Europe, representing scientists, obesity specialists, physicians, healthcare practitioners, public health practitioners and patients. Established in 1986, EASO is a federation of professional membership associations from 34 countries.
The World Obesity Federation represents professional members of the scientific, medical and research communities from over 50 regional and national obesity associations. Through their membership they create a global community of organisations dedicated to solving the problems of obesity.
Founded in 1982, The Obesity Society (TOS) is the leading professional society focused on obesity science, treatment and prevention. Their approximately 2,400 members worldwide range from early career to established members of the field, including basic and clinical researchers, clinicians and care providers, educators, early career investigators and students. Their mission is to promote innovative research, effective and accessible care, and public health initiatives that will reduce the personal and societal burden of obesity.
The Obesity Action Coalition (OAC) is a more than 59,000 member-strong US-based national non-profit organization dedicated to giving a voice to the individual affected by the disease of obesity and helping individuals along their journey toward better health through education, advocacy and support. Their core focuses are to raise awareness and improve access to the prevention and treatment of obesity, provide evidence-based education on obesity and its treatments, fight to eliminate weight bias and discrimination, elevate the conversation of weight and its impact on health and offer a community of support for the individual affected.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in health care. This heritage has given them experience and capabilities that also enable them to help people defeat serious chronic conditions: diabetes, haemophilia, growth disorders and obesity. Novo Nordisk uses their experience to help facilitate relationships between key stakeholders and support them in their efforts to map national challenges, build capabilities and define the path to effective obesity care.